VolitionRX (NYSEAMERICAN:VNRX) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of VolitionRX (NYSEAMERICAN:VNRX) in a report released on Wednesday,Benzinga reports. D. Boral Capital currently has a $3.00 price target on the medical research company’s stock.

Separately, Maxim Group lowered shares of VolitionRX from a “buy” rating to a “hold” rating in a research report on Wednesday, December 3rd. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $2.50.

VolitionRX Stock Up 5.3%

NYSEAMERICAN VNRX opened at $0.20 on Wednesday. The company’s 50-day simple moving average is $0.24 and its 200 day simple moving average is $0.37. The stock has a market cap of $27.11 million, a P/E ratio of -0.87 and a beta of 1.33. VolitionRX has a twelve month low of $0.17 and a twelve month high of $0.94.

Institutional Trading of VolitionRX

Several institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC acquired a new stake in shares of VolitionRX during the fourth quarter worth about $28,000. Virtu Financial LLC boosted its holdings in shares of VolitionRX by 166.6% in the 4th quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock valued at $28,000 after buying an additional 67,848 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in VolitionRX in the fourth quarter valued at $34,000. Northwestern Mutual Wealth Management Co. acquired a new stake in VolitionRX in the 2nd quarter valued at about $52,000. Finally, Silverberg Bernstein Capital Management LLC lifted its position in shares of VolitionRX by 15.6% in the third quarter. Silverberg Bernstein Capital Management LLC now owns 232,082 shares of the medical research company’s stock valued at $157,000 after buying an additional 31,300 shares during the last quarter. Institutional investors own 8.09% of the company’s stock.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.